Novartis | NOVN - Equity Capital And Reserves


Novartis reported $38.93B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Alcon AG USD 22.13B 99M Mar/2026
Almirall EUR 1.49B 24.03M Dec/2025
Amgen USD 9.19B 532M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
Autolus Therapeutics Ltd USD 108.83M 69.3M Mar/2026
Bayer EUR 28.85B 2.9B Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Eli Lilly USD 31.2B 4.66B Mar/2026
Fresenius EUR 19.77B 1.14B Dec/2025
Fresenius Medical Care EUR 14.2B 13.95B Mar/2026
Genmab DKK 5.85B 96M Dec/2025
Gilead Sciences USD 23.52B 897M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
GRIFOLS EUR 5.46B 171M Mar/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
J&J USD 81.19B 358M Mar/2026
Lakefront Biotherapeutics EUR 3.25B 17.5M Mar/2026
Lonza CHF 9.13B 513M Dec/2025
Merck EUR 29.74B 1.15B Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Novartis USD 46.13B 1.8B Dec/2025
Novo Nordisk DKK 203.07B 9.02B Mar/2026
Orion EUR 1.12B 162.1M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Philips EUR 11.39B 403M Mar/2026
Recordati EUR 2.06B 140.52M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 72.81B 1.1B Mar/2026
UCB EUR 10.87B 1.18B Dec/2025